Aravive Inc (VSAR)
Aravive is an endocrine-focused biopharmaceutical company that engaged in developing a long-acting form of recombinant human growth hormone (rhGH), somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease that affects pediatric and adult patients. Somavaratan is a fusion protein consisting of rhGH and a proprietary half-life extension technology known as XTEN. Somavaratan includes a long N-terminal XTEN sequence, XTEN1, which is added to rhGH as a fusion protein, increasing the hydrodynamic size of the rhGH and thereby reducing glomerular filtration. A C-terminal XTEN sequence, XTEN2, is also added to reduce receptor mediated clearance by decreasing receptor binding.
|
March 28, 2024 9:50 AM Eastern
Hold (2.00 out of 4)
100th percentile
|
|